Fortrea Holdings (FTRE) Profit After Tax (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Profit After Tax came in at -$13.2 million in Q2 2026, up 96.48% YoY from -$6.7 million in Q2 2025, and up 48.03% on a QoQ basis from -$25.4 million in Q1 2026.
Analysis
Fortrea Holdings (FTRE) Profit After Tax (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Profit After Tax data on file, last reported at -$13.2 million in Q2 2026.
- Quarterly Profit After Tax rose 96.48% year-over-year to -$13.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$87.0 million (up 91.53% YoY) and the FY2025 annual result came in at -$986.2 million, down 200.21% from the prior year.
- Profit After Tax improved to -$13.2 million in Q2 2026, from -$25.4 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $60.6 million in Q3 2022 to a low of -$562.9 million in Q1 2025.
- A 5-year average of -$81.0 million and a median of -$27.9 million in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2023 — Profit After Tax soared 137.38% — and 2024, when it tumbled 628.8%.
- Tracing FTRE's Profit After Tax over 5 years: stood at $26.7 million in 2022, then plunged by 328.46% to -$61.0 million in 2023, then decreased by 0.33% to -$61.2 million in 2024, then surged by 46.9% to -$32.5 million in 2025, then surged by 59.38% to -$13.2 million in 2026.
- The last three Profit After Tax figures came in at -$13.2 million (Q2 2026), -$25.4 million (Q1 2026), and -$32.5 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.70 Bn | 58.52 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 57.56 Bn | 52.42 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.16 Bn | 35.06 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.63 Bn | 32.32 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.63 Bn | 27.79 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Fortrea Holdings | 1.73 Bn | 1.56 Bn | 139.20 Mn | -13.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -13.20 Mn |
| Mar 31, 2026 | -25.40 Mn |
| Dec 31, 2025 | -32.50 Mn |
| Sep 30, 2025 | -15.90 Mn |
| Jun 30, 2025 | -374.90 Mn |
| Mar 31, 2025 | -562.90 Mn |
| Dec 31, 2024 | -61.20 Mn |
| Sep 30, 2024 | -27.90 Mn |
| Jun 30, 2024 | -138.40 Mn |
| Mar 31, 2024 | -101.00 Mn |
| Dec 31, 2023 | -61.00 Mn |
| Sep 30, 2023 | -16.10 Mn |
| Jun 30, 2023 | 32.00 Mn |
| Mar 31, 2023 | 19.10 Mn |
| Dec 31, 2022 | 26.70 Mn |
| Sep 30, 2022 | 60.60 Mn |
| Jun 30, 2022 | -85.60 Mn |